Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer - Concepedia

Concepedia

Publication | Open Access

Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer

DOI Full Paper Access

190

Citations

31

References

2019

Year

Kyle C. Cuneo, Meredith A. Morgan, Vaibhav Sahai, Matthew J. Schipper, Leslie A. Parsels, Joshua D. Parsels, Theresa P. Devasia, Mahmoud Al-Hawaray, Clifford S. Cho, Hari Nathan,

Journal of Clinical Oncology

Abstract

AZD1775 in combination with gemcitabine and radiation therapy was well tolerated at a dose that produced target engagement in a surrogate tissue. The overall survival is substantially higher than prior results combining gemcitabine with radiation therapy and warrants additional investigation.

References

	Year	Citations

Page 1